Menu
NovaSight’s management is comprised of experienced executives bringing broad and multidisciplinary expertise in the field of vision care.
Ran has decades of experience in developing optics and medical devices. In his previous position as VP R&D for Visionix, a global leader in eye care solutions, he was responsible for developing innovative, cutting edge eye diagnostics products. Ran holds a BSc in Mechanical Engineering and has nine patents to his name.
Dan, an electronics engineer, was the co-founder of Sightline Technologies, which was acquired by Stryker for US$50 million. He holds 11 patents, with additional patents pending.
Oren holds a PhD in Neuroscience, specializing in binocular vision, and a BSc in Optometry, with extensive hospital experience. He has published more than 20 scientific publications and holds five patents, with additional patents pending.
Danny served in various operational and financial positions in Hi-Tech companies. In his previous position as VP Operations for Visionix, a global leader in eye care solutions, he was responsible for the financial and manufacturing departments. Danny is a Certified Public Accountant (CPA) and holds B.B. & MBA in Business Management and Accounting.
Liron has extensive experience in executive sales and marketing positions in the medical and assistive devices field, taking leadership roles within industry-leading companies such as OrCam Technologies and IOPtima. Liron holds a BA and an MSc in Applied Economics.
Drew Hopper is an award winning Global Commercial Executive with a history of growing brands from acquisition to market leader for companies such as Alcon & Stryker. While at Sight Sciences, he was a member of the executive team behind the largest MedTech IPO in NASDAQ history. Drew holds a Bachelor of Arts from Capital University and an MBA in Marketing and Strategic Leadership from Southern Methodist University.
Complementing the leadership are a team of passionate, diverse and determined problem solvers.
© 2022 NovaSight | All Rights Reserved | NS-00779-R08
CureSight™ and EyeSwift®PRO devices are CE marked in accordance with EU Medical Device Regulation 2017/745.
CureSight™ is an FDA 510(K) cleared device.
Caution: The EyeSwift®PRO system is an Investigational Device, Limited By Federal (Or United States) Law To Investigational Use.
Currently, TrackSightTM is not approved for sales in any country.
Your data will be handled in accordance with our Privacy Policy. In the event that a child’s or minor’s information is being submitted as part of this form, we hereby request that such information be submitted solely by the legal guardian of such child or minor.
This website uses cookies for functional, operational, analytical and advertising purposes. Please review our Privacy Policy for more information
